SCHEMBL5316220

SCHEMBL5316220

CC(=O)Oc1ccc(S(=O)(=O)Nc2ccc(C(C)=O)cc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.68
HPGD P15428 3/20 0.68
CA12 O43570 1/20 0.66
CA9 Q16790 1/20 0.66
ALDH1A1 P00352 5/20 0.63
MEN1 O00255 4/20 0.63
KMT2A Q03164 4/20 0.63
LMNA P02545 3/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
GAA P10253 2/20 0.60
ALOX12 P18054 1/20 0.60
GFER P55789 1/20 0.56
POLB P06746 2/20 0.55
TP53 P04637 3/20 0.55
HDAC3 O15379 1/20 0.54
HDAC4 P56524 1/20 0.54
HDAC1 Q13547 1/20 0.54
HDAC7 Q8WUI4 1/20 0.54
HDAC2 Q92769 1/20 0.54
HDAC10 Q969S8 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4090549 0.87 MAPT (0.70) MAPTHPGDCA12CA9ALDH1A1
SCHEMBL14394822 0.86 MAPT (0.62) MAPTHPGDCA12CA9ALDH1A1
SCHEMBL27889025 0.85 CA12 (0.65) MAPTCA12CA9ALDH1A1MEN1
SCHEMBL15702654 0.83 MAPT (0.83) MAPTHPGDCA12CA9ALDH1A1
SCHEMBL14567935 0.83 GFER (0.80) MAPTHPGDCA12CA9ALDH1A1
SCHEMBL15705237 0.82 FFAR1 (0.68) MAPTHPGDCA12CA9ALDH1A1
SCHEMBL4806773 0.82 HDAC1 (0.72) MAPTHPGDCA12CA9ALDH1A1
SCHEMBL4814781 0.82 HDAC1 (0.72) MAPTHPGDCA12CA9ALDH1A1
SCHEMBL3767094 0.81 MAPT (1.00) MAPTHPGDCA12CA9ALDH1A1
SCHEMBL12338982 0.81 MAPT (1.00) MAPTHPGDCA12CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007067994-A1 INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2007-06-14 WO disclosed
WO-2007067993-A1 INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2007-06-14 WO disclosed
WO-2007067993-A1 INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2007-06-14 WO disclosed
WO-2007067994-A1 INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2007-06-14 WO disclosed
US-20070135431-A1 INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE KALYPSYS, INC (US) 2007-06-14 US disclosed
US-20070135431-A1 INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE KALYPSYS, INC (US) 2007-06-14 US disclosed
US-20070135431-A1 INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE KALYPSYS, INC (US) 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135431-A1 INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE HDAC6, HDAC1, HDAC3 MAPT 401/4885HPGD 806/4885CA12 2934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.